A fusion protein with improved thrombolytic effect and low bleeding risk

Summary

To resolve the therapeutic dilemma between efficacy of thrombolysis and bleeding risk associated with the use of a combination of thrombolytic and anticoagulant treatments, we created a fusion protein. Staphylokinase was fused to the N-terminus of hirudin using thrombin recognition sequence as linker peptide, resulting in a fusion protein STH.We hypothesised that STH would be cleaved by thrombin at the thrombus site, releasing staphylokinase and hirudin to perform bifunctionally, and attenuating bleeding risk. SDS-PAGE andWestern blot analyses indicated that the linker peptide could be specially recognised and cleaved by thrombin. Amidolytic and thromboelastogram assays showed that the N-terminus of hirudin in STH was blocked by staphylokinase and linker peptide, impeding hirudin’s anticoagulant activity. Once cleaved, STH displayed 35.7% of the anticoagulant activity of equimolar hirudin and exhibited anticoagulant effects in the fibrin clot lysis assay.Thrombin-binding and fibrin clot lysis assays showed that the C-terminus of hirudin retained its high affinity for thrombin. Moreover, STH showed improved thrombolytic effects and a lower bleeding risk in animals. Thus, STH may have the capacity to perform bifunctionally and release anticoagulant activity in a thrombus-targeted manner in vivo, which may reduce the bleeding risk that often accompanies high thrombolytic efficacy in the treatment of thromboembolic diseases.

Keywords

Fusion protein - staphylokinase - hirudin - thrombolysis - bleeding

^* These authors contributed equally to this work.

• References

• 1 Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93: 627-628.
• 2 The InTIME-IIinvestigators. Intravenous NPA for the treatment of infarcting myocardium early, InTIMEII, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-2013.
• 3 Fitchett D. Tailored antithrombotic therapy for acute coronary syndromes. Expert Rev Cardiovasc Ther 2008; 06: 935-944.
• 4 French JK, Edmond JJ, Gao W. et al. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction. Am J Cardiovasc Drugs 2004; 04: 107-115.
• 5 Eikelboom JW, Quinlan DJ, Mehta SR. et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction-a Metaanalysis of the randomized trials. Circulation 2005; 112: 3855-3867.
• 6 Wong CK, White HD. Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine. Am J Cardiovasc Drugs 2007; 07: 249-257.
• 7 Icke C, Schlott B, Ohlenschlager O. et al. Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations. Mol Pharmacol 2002; 62: 203-209.
• 8 Lian Q, Szarka SJ, Ng KK. et al. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots. J Biol Chem 2003; 278: 26677-26686.
• 9 Szemraj J, Walkowiak B, Kawecka I. et al. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant I. In vitro study. J Thromb Haemost 2005; 03: 2156-2165.
• 10 Wirsching F, Luge C, Schwienhors A. Modular design of a novel chimeric protein with combined thrombin inhibitory activity and plasminogen-activating potential. Mol Gen Metab 2002; 75: 250-259.
• 11 Sau-Ching W, Francis J, Sui-Lam W. A fast-acting,modular-structured staphylokinase fusion with Kringle 1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy. J Bio Chem 2003; 278: 18199-18205.
• 12 Szemraj J, Stankiewicz A, Rozmyslowicz-Szerminska W. et al. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant An in-vivo study. Thromb Haemost 2007; 97: 1037-1045.
• 13 Shi BX, Yu AP, Liu YY. et al. Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk. J Thromb Thrombolysis 2007; 24: 283-292.
• 14 Yu AP, Zhang CL, Dong CN. et al. Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release of anticoagulant activity. Chin J Biotech 2008; 24: 1955-1961.
• 15 Zhang CL, Yu AP, Yuan B. et al. Construction and functional evaluation of hirudin derivatives with low bleeding risk. Thromb Haemost 2008; 99: 324-330.
• 16 Sheffield WP, Eltringham-Smith LJ, Gatalance S. et al. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo. Thromb Haemost 2009; 101: 867-877.
• 17 Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation 2007; 116: 305-315.
• 18 Elg M, Borjesson I, Carlsson S. Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat. Biopharm Drug Dispos 2003; 24: 251-257.
• 19 Monreal M, Silveira P, Monreal L. et al. Comparative study on the antithrombotic efficacy of four low-molecular-weight heparins in three different models of experimental venous thrombosis. Haemostasis 1991; 21: 91-97.
• 20 Wallace A, Dennis S, Hofsteenge J. et al. Contribution of the N-terminal region of hirudin to its interaction with thrombin. Biochemistry 1989; 28: 10079-10084.
• 21 Fortkamp E, Rieger M, Heisterberg-Moutses G. Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech. DNA 1986; 05: 511-517.